Internal medicine

Endocrinology

Receptor

Glucagon-like peptide 1 receptor

Adverse effect

Glucagon-like peptide-1

Type 2 diabetes

Agonist

Diabetes mellitus

Medicine

New England Journal of Medicine

Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GLP-1 receptor agonist, efpeglenatide, on cardiovascular and renal outcomes in patients with type 2 diabetes who are also at high risk for adverse cardiovascular events is uncertain.

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes